ArticleExperimental hematology & oncology2020

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.

Vivek Subbiah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.